Skip to main content

Concordia

Question for Department of Health

UIN 117626, tabled on 5 December 2017

To ask the Secretary of State for Health, what steps he plans to take against Concordia as a result of the Competition and Markets Authority findings announced on 21 November 2017 that Concordia had overcharged the NHS for the provision of Liothyronine tablets.

Answered on

12 December 2017

The Competition and Markets Authority has provisionally found that Concordia abused its dominant position to overcharge the National Health Service by millions for liothyronine tablets. A provisional decision does not necessarily lead to an infringement decision. Where companies have breached competition law, the Department will seek damages and invest that money back into the NHS.

Answered by

Department of Health and Social Care
Named day
Named day questions only occur in the House of Commons. The MP tabling the question specifies the date on which they should receive an answer. MPs may not table more than five named day questions on a single day.